Spain Pharmaceutical Market Analysis, 2010-2014

Having displayed fluctuating growth rates in the years 2005-2009 the Spain pharmaceuticals market is expected to stabilize and starting from 2009 the market is estimated to show the slight deceleration in growth over the years up to 2014.

The Spain pharmaceuticals market generated total revenues of $18,483.5 million in 2009, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2005-2009. In comparison, the French and German markets grew with CAGRs of 3.2% and 3.1% respectively, over the same period, to reach respective values of $37,306.2 million and $37,139.2 million in 2009.

Cardiovascular sales proved the most lucrative for the Spain pharmaceuticals market in 2009, gene-rating total revenues of $4,031 million, equivalent to 21.8% of the market's overall value. In comparison, central nervous system sales generated revenues of $2,915.1 million in 2009, equating to 15.8% of the market's aggregate revenues

This report highlights the Spain pharmaceutical sector in terms of market share, key trends, market players and competitive scenario in the market.

Key Highlights:
- Current market scenario of Spain pharmaceutical market, by revenue, geographic regions, product types, and market players.
- Competitive analysis of the pharmaceutical sector by each country via-a-vis global market
- Market forecast of Spain Pharmaceuticals market, by revenue till 2014.
- Covered more than 12 company profiles in the pharmaceutical sector covering their performance, key financials, SWOT analysis, and investment analysis.

Venn Research, in association to its network of partners provides information and research to thousands of clients worldwide. The information provided herein has been obtained from reliable sources to provide a holistic survey on the market dynamics. SHOW LESS READ MORE >

1 Spain Pharmaceuticals Market, 2010
1.1 Quick Glance at the Market
1.2 Market Scenario
2 Spain Pharmaceuticals Market, By Categories, 2010
3 Spain Pharmaceuticals Market, By Market Players, 2010
4 Spain Pharmaceuticals Market Outlook, 2011-2014
5 Spain Pharmaceuticals Market - Competitive Analysis
6 Company Profiles
6.1 Almirall Prodesfarma SA
6.1.1 Key Financials
6.1.2 Overview
6.1.3 Subsidiaries
6.1.4 Products and Services Analysis
6.1.5 Research and Development
6.2 Astellas Pharma
6.2.1 Key Financials
6.2.2 Overview
6.2.3 Subsidiaries
6.2.4 Products And Services Analysis:
6.2.5 SWOT Analysis
6.2.6 Company View
6.3 AstraZeneca PLC
6.3.1 Overview
6.3.2 Subsidiaries
6.3.3 Products and Services Analysis
6.3.4 Competitor Analysis
6.3.5 SWOT Analysis
6.4 The Menarini Group
6.4.1 Overview
6.4.2 Subsidiaries
6.4.3 Competitor Analysis
6.4.4 SWOT Analysis
6.5 EGIS Pharmaceuticals Plc
6.5.1 Overview
6.5.2 Subsidiaries
6.5.3 Products and Services Analysis
6.5.4 SWOT Analysis
6.6 Gedeon Richter Ltd
6.6.1 Overview
6.6.2 Subsidiaries
6.6.3 Competitor Analysis
6.6.4 SWOT Analysis
6.6.5 Investment Analysis
6.7 GlaxoSmithKline Plc
6.7.1 Key Financials
6.7.2 Overview
6.7.3 Subsidiaries
6.7.4 Products and Services Analysis
6.7.5 Competitor Analysis
6.7.6 SWOT Analysis
6.7.7 Investment Analysis
6.8 Les Laboratoires Servier
6.8.1 Overview
6.8.2 Competitor Analysis
6.8.3 SWOT Analysis
6.9 Novartis AG
6.9.1 Key Financials
6.9.2 Overview
6.9.3 Segments
6.9.4 Products and Services Analysis
6.9.5 Competitor Analysis
6.9.6 SWOT Analysis
6.10 Nycomed International Management GmbH
6.10.1 Key Financials
6.10.2 Overview
6.10.3 Products and Services Analysis
6.10.4 Competitor Analysis
6.10.5 SWOT Analysis
6.11 Orifarm A/S
6.11.1 Overview
6.12 Pharmstandard
6.12.1 Overview

List of Tables:
Table 1: Spain Pharmaceuticals Market, ($billions) 2005-2010
Table 2: Spain Pharmaceuticals Market, By Categories, 2010
Table 3: Spain Pharmaceuticals Market, By Market Players, 2010
Table 4: Spain Pharmaceuticals Market Outlook, ($billions) 2011-2014
Table 4: Almirall Prodesfarma SA - Key Financials, 2008-2009
Table 5: Almirall Prodesfarma SA Sales, By Distribution Channels
Table 6: Almirall Prodesfarma SA Sales, By Geography
Table 7: Almirall Prodesfarma SA Sales, By Therapeutic Area
Table 8: Almirall Prodesfarma SA Sales, By Brand Names
Table 9: Astellas Pharma - Key Financials, 2008-2010
Table 10: Astellas Pharma - Historical Stock Information
Table 11: Astellas Pharma Sales, By Geography
Table 12: Astellas Pharma Sales, By Products
Table 13: AstraZeneca Sales, By Products, 2009
Table 14: AstraZeneca Sales, By Geography, 2009
Table 15: The Menarini Group Sales 2009
Table 16: The Menarini Group Employees, 2009
Table 17: Gedeon Richter Plc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2010
Table 18: Gedeon Richter Plc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2010
Table 19: GlaxoSmithKline Plc - Key Financials
Table 20: GlaxoSmithKline Plc - Histroical Stock Information
Table 21: GlaxoSmithKline Plc Sales, By Geography, 2009
Table 22: GlaxoSmithKline Plc Sales, By Products and Services, 2009
Table 23: GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2010
Table 24: GlaxoSmithKline plc, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2010
Table 25: GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2010
Table 26: GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Sector, 2005 to YTD 2010
Table 27: Novartis AG - Key Financials
Table 28: Novartis AG - Historical Stock Information
Table 29: Novartis AG Sales, By Products and Servces, 2009
Table 30: Novartis AG Pharmaceuticals Sales, 2009
Table 31: Novartis AG Sales, By Geogrphy, 2009
Table 32: Nycomed International Management GmbH - Key Financials
Table 33: Orifarm A/S - Key Financials

List of Figures:
Figure 1: Spain Pharmaceuticals Market, ($billions) 2005-2010
Figure 2: Spain Pharmaceuticals Market, By Categories, 2010
Figure 3: Spain Pharmaceuticals Market, By Market Players, 2010
Figure 4: Spain Pharmaceuticals Market Outlook, ($billions) 2011-2014
Figure 6: Almirall Prodesfarma SA Sales, By Geography
Figure 7: Almirall Prodesfarma SA - Research and Development Growth, 2011-2013

Almirall Prodesfarma SA
Astellas Pharma
AstraZeneca PLC
The Menarini Group
EGIS Pharmaceuticals Plc
Gedeon Richter Ltd
GlaxoSmithKline Plc
Les Laboratoires Servier
Novartis AG
Nycomed International Management GmbH
Orifarm A/S
Pharmstandard